{"id":12832,"date":"2020-02-24T10:44:20","date_gmt":"2020-02-24T09:44:20","guid":{"rendered":"https:\/\/ellipse.prbb.org\/?p=12832"},"modified":"2020-02-24T10:42:07","modified_gmt":"2020-02-24T09:42:07","slug":"el-disseny-dinhibidors-especifics-de-parp-millorarien-lefectivitat-en-el-tractament-del-cancer","status":"publish","type":"post","link":"https:\/\/ellipse.prbb.org\/ca\/el-disseny-dinhibidors-especifics-de-parp-millorarien-lefectivitat-en-el-tractament-del-cancer\/","title":{"rendered":"El disseny d&#8217;inhibidors espec\u00edfics de PARP millorarien l&#8217;efectivitat en el tractament del c\u00e0ncer"},"content":{"rendered":"<p>Per tal de que les nostres c\u00e8l\u00b7lules funcionin correctament, necessitem enzims. Les <strong>Poli ADP ribosa polimerases (PARP)<\/strong> formen una fam\u00edlia d&#8217;enzims involucrats en alguns processos cel\u00b7lulars tals com la\u00a0<strong>reparaci\u00f3 de l&#8217;ADN<\/strong>. Degut a que aquesta fam\u00edlia d&#8217;enzims duu a terme funcions clau en la divisi\u00f3 cel\u00b7lular, cient\u00edfics i cient\u00edfiques han dissenyat\u00a0<strong>inhibidors PARP<\/strong>, considerats un\u00a0<strong>tractament potencial pel c\u00e0ncer<\/strong>.<\/p>\n<p>Recentment, personal investigador de l&#8217;<a href=\"http:\/\/www.imim.es\/\" target=\"_blank\" rel=\"noopener\">Institut Hospital del Mar d\u2019Investigacions M\u00e8diques\u00a0(IMIM)<\/a>\u00a0ha demostrat que\u00a0<strong><a href=\"https:\/\/www.imim.es\/noticies\/870\/un-estudi-indica-la-importancia-de-dissenyar-inhibidors-especifics-per-parp-1-i-parp-2-per-millorar-la-seva-efectivitat-contra-el-cancer\" target=\"_blank\" rel=\"noopener\">la defici\u00e8ncia espec\u00edfica de PARP-1 o PARP-2<\/a>\u00a0<\/strong><span lang=\"en\">\u2014 membres de la familia PARP\u00a0\u2014\u00a0<strong>en limf\u00f2cits T<\/strong> permet una\u00a0<strong>millor resposta antitumoral, <\/strong>mentre que\u00a0la\u00a0<strong>resposta antitumoral<\/strong>\u00a0\u00e9s <strong>pitjor <\/strong>quan es dona una\u00a0<strong>doble defici\u00e8ncia de PARP-1 i PARP-2<\/strong>.<\/span><\/p>\n<p>\u00abActualment, tots els f\u00e0rmacs inhibidors de PARP disponibles actuen de la mateixa manera davant de les dues prote\u00efnes, PARP-1 i PARP-2, per\u00f2 els nostres resultats indiquen que seria molt important desenvolupar f\u00e0rmacs m\u00e9s selectius que inhibeixin de manera espec\u00edfica cadascuna d&#8217;elles, per aix\u00ed aconseguir una millor resposta contra el tumor\u00bb, conclou <strong>Jos\u00e9 Y\u00e9lamos<\/strong>, coordinador de grup a l&#8217;IMIM i l\u00edder de l&#8217;estudi.<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Personal investigador de l&#8217;IMIM demostra que la defici\u00e8ncia espec\u00edfica de PARP-1 o PARP-2 en limf\u00f2cits T proporciona una millor resposta antitumoral que inhibir els dos tipus alhora.<\/p>\n","protected":false},"author":9,"featured_media":12825,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[26],"tags":[275,312,271,213],"new-type":[35],"class_list":["post-12832","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recerca","tag-adn","tag-cancer-ca","tag-divisio-cellular","tag-imim","new-type-noticies"],"acf":[],"_links":{"self":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/12832","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/comments?post=12832"}],"version-history":[{"count":5,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/12832\/revisions"}],"predecessor-version":[{"id":12849,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/12832\/revisions\/12849"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/media\/12825"}],"wp:attachment":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/media?parent=12832"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/categories?post=12832"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/tags?post=12832"},{"taxonomy":"new-type","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/new-type?post=12832"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}